1.     Liu CY, Shiau CW, Cheng AL, Kuo HY, Tzeng CH, Chen KF. Bortezomib selectively induces apoptosis in hematological malignant cells through down-regulation of phospho-Akt independent of its proteasome inhibitory activity. AACR Meeting Abstracts, Apr 2010; 2010: 1575.

2.     Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. AACR Meeting Abstracts, Apr 2010; 2010: 355.

3.     Tseng LM, Liu CY, Chang KC, Shiau CW, Cheng AL, Kuo HY, Tzeng CH , Chen KF. CIP2A mediates the apoptotic effect of bortezomib on triple negative breast cancer cells. AACR Meeting Abstracts, Apr 2011; 2011: 2622.

4.     Liu CY, Shiau CW, Kuo HY, Cheng AL, Tzeng CH, Chen KF. A novel obatoclax derivative is a promising agent to overcome bortezomib’s resistance in acute leukemia cells. AACR Meeting Abstracts, Apr 2011; 2011: 4515.

5.     Chen KF , Su JC, Chen WL, Liu CY, Cheng AL, Chen PJ, Shiau CW. SC-2001, a SHP-1 enhancer, induces apoptosis in hepatocellular carcinoma through SHP-1 dependent STAT3 inactivation. AACR Meeting Abstracts, Apr 2011; 2011: 4516. 

6.     Liu CY, Shiau CW, Kuo HY, Huang HP, Tzeng CH, Chen KF. Cellular inhibitor of protein phosphatase 2a determines bortezomib-induced apoptosis in acute leukemia cells. 16th Congress of the European Hematology Association (EHA) June 2011, abstract No. 247 (code 208) 

7.     Tseng LM , Liu CY, Kao YP, Shiau CW, Su JC, Chang KC, Chen KF. Anti-tumor effects of SC-2001, a novel STAT3 inhibitor, in breast cancer cells. AACR Meeting Abstracts, Apr 2012; 2012: 4724.

8.     Liu CY, Tseng LM, Chang KC, Shiau CW, Su JC, Chen KF. A novel sorafenib-derivative SC-1 induces apoptosis in breast cancer cells through STAT3 inhibition. AACR Meeting Abstracts, Apr 2012; 2012: 3844

9.     Liu CY, Tseng LM, Chang KC, Shiau CW, Su JC, Chen KF. Novel sorafenib-derivatives induce apoptosis in breast cancer cells through STAT3 inhibition. 2012 CTRC−AACR San Antonio Breast Cancer Symposium, December 4−8, 2012. Abstract P6-11-05

10.   Tseng LM, Liu CY, Chang KC, Wang DS, Shiau CW, Chen KF. CIP2A mediates the effect of tamoxifen-induced apoptosis in estrogen receptor negative breast cancer cells. AACR Meeting Abstracts, Apr 2013; 2013: 914

11.   Liu CY, Tseng LM, Chang KC, Chu PY, Su JC, Tai WT, Shiau CW, Chen KF. Sorafenib analogues SC-1 and SC-43 show better apoptotic effects than sorafenib through SHP-1 dependent STAT3 inhibition in breast cancer cells. AACR Meeting Abstracts, Apr 2013; 2013: 3250. (AACR award)

12.   Oral presentation: Liu CY et al. A novel proteasome independent target of bortezomib in leukemia cells. The 75th Annual Meeting of the Japanese Society of Hematology, Oct 11-13, 2013: OS-1-98

13.   Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Shiau CW, Chen KF. Obatoclax analogue SC-2001 inhibits STAT3 phosphorylation by enhancing protein tyrosine phosphatase SHP-1 expression and induces apoptosis in human breast cancer cells. AACR Meeting Abstracts, Apr 2014; 2014: 3803

14.   Tseng LM, Liu CY, Hsu CJ, Wang DS, Su JC, Shiau CW, Chen KF. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. AACR Meeting Abstracts, Apr 2014; 2014: 2778

15.   Poster presentation (Travel Award): Liu CY et al. Transcriptionally regulated CIP2A mediates carfilzomib-induced apoptosis in leukemia cells. The 76th Annual Meeting of the Japanese Society of Hematology, Oct 31- Nov 2, 2014: PS-1-46.

16.   Liu CY, Tsai WC, Hung MH, Yu YB, Ko PS, Hunag CT, Shiau CW, Chen K. Carfilzomib transcriptionally regulates CIP2A/PP2A/p-Akt signaling and induces apoptosis in leukemia cells. AACR Meeting Abstracts, Apr 2015; 2015: 1737.

17.   Tseng LM, Liu CY, Yang SP, Wang WL, Su JC, Wu CY, Shiau CW, Chen KF. Sequential combination of docetaxel with a novel SHP-1 agonist enhanced anti-tumor effect in triple negative breast cancer cells. AACR Meeting Abstracts, Apr 2015; 2015: 4465.

18.   Poster presentation (Travel Award): Liu CY et al. Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma. The 77th Annual Meeting of the Japanese Society of Hematology, Oct 16- Oct 18, 2015: PS-2-157.

19.   Man-Hsin Hung, Chia-Jen Liu, Ta-Chung Chao, Cheng-Hwai Tzeng, Chun-Yu Liu. The risk of second primary malignancy among male breast cancer patients: A population-based study. ASCO 2014 meeting abstract #1594.

20.   20th Taiwan Joint Cancer Conference (TJCC) 2015: Abstract 20th-C2-003: A novel erlotinib derivative TD52 inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.

21.   20th Taiwan Joint Cancer Conference (TJCC) 2015: Abstract 20th-C1-012: Sequential combination of docetaxel with a novel SHP-1 agonist enhanced anti-tumor effect in triple negative breast cancer cells.

22.   2014 ABCC poster presentation (Oct 17 to 19, 2014): RFX-1 upregulated SHP-1 expression and SHP-1-dependent STAT3 inactivation determines an obatoclax analogue SC-2001 induced apoptosis in human breast cancer cells.

23.   Impact of kynurenine 3-monooxygenase expression on outcome in patients with triple-negative breast cancer undergone primary treatments. 2015 San Antonio Breast Cancer Symposium (SABCS), December 8-12, 2015. Abstract P2-08-25.

24.   Liu CY,  Lee CH, Huang CT,  Chu PY, Wang WL, Tseng LM, Shiau CW,  Chen KF Nintedanib induces anti-tumor effects in triple negative breast cancer cells by targeting SHP-1/p-STAT3 mediated signaling pathway. AACR Meeting Abstracts, Apr 2016; 2016: 1261.

25.   Tseng LM, Chen YT, Huang CT, Chu PY, Wang WL, Liu CY, Shiau CW, Chen KF Erlotinib derivative, devoid of EGFR kinase inhibiting effect, induced apoptosis of triple negative breast cancer cells through modulating Elk-1/CIP2A signaling pathway. AACR Meeting Abstracts, Apr 2016; 2016: 3065.

26.   Su JC, Chiu HC, Liu CY, Chen KF, Shiau CW. Disrupting p-STAT3-mediated VEGF-A paracrine and autocrine feed-forward loops by targeting SHP1 suppresses triple negative breast cancer cell metastasis. AACR Meeting Abstracts, Apr 2016; 2016: 3825.

27.   21th Taiwan Joint Cancer Conference (TJCC) 2016 May: Abstract 21th-T7-021: Analysis the impact of kynurenine 3-monooxygenase expression on outcome in patients with triple-negative breast cancer undergone primary treatment.

28.   21th Taiwan Joint Cancer Conference (TJCC) 2016 May: Abstract 21th-B1-021: An erlotinib derivative induces apoptosis and enhances chemosensitivity through EGFR-independent reactivation of protein phosphatase 2A and disrupting CIP2A-PP2A feedforward loop in triple negative breast cancer cells.

29.   21th Taiwan Joint Cancer Conference (TJCC) 2016 May: Abstract 21th-B1-023: Proteasome inhibitor carfilzomib induces leukemia cells apoptosis via proteasome inhibition-independent mechanism: through downregulation of Elk-1-regulated CIP2A signaling pathway.

30.   21th Taiwan Joint Cancer Conference (TJCC) 2016 May: Abstract 21th-B1-025: Investigation of combination effects of a novel agonist of the protein tyrosine phosphatase SHP-1 with chemotherapeutics -- Docetaxel, Taxol and Cisplatin in triple negative breast cancer cells.

31.   21th Taiwan Joint Cancer Conference (TJCC) 2016 May: Abstract 21th-B1-022: Multi-targeted tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple negative breast cancer cells.

32.   21th Taiwan Joint Cancer Conference (TJCC) 2016 May: Abstract 21th-B1-024: A sorafenib analogue, SC-60, induces apoptosis through SHP-1/STAT3 pathway and shows enhanced apoptosis in combination with docetaxel in triple-negative breast cancer cells.

33.   21th Taiwan Joint Cancer Conference (TJCC) 2016 May: Abstract 21th-B1-052: Disrupting p-STAT3-mediated VEGF-A paracrine and autocrine feed-forward loops by targeting SHP-1 suppresses triple negative breast cancer cell metastasis.

34.   22th Taiwan Joint Cancer Conference (TJCC) 2017 May: Abstract 22nd-B1-026: CIP2A/PP2A/p-ERK/p-Elk-1 oncogenic loop contribute to triple negative breast cancer aggressiveness and can be interfered by inhibiting SET.

35.   22th Taiwan Joint Cancer Conference (TJCC) 2017 May: Abstract 22nd-B1-028: Kynurenine-3-monooxygenase promotes triple negative breast cancer progression.

36.   22th Taiwan Joint Cancer Conference (TJCC) 2017 May: Abstract 22nd-B1-029: Pan-HER inhibitor varlitinib (ASLAN001) induces triple negative breast cancer cell apoptosis through inhibiting HER/ERK pathway

37.   Liu CY, Huang TT, Huang CT,  Yang HP, Tseng LM, Shiau CW, Chen KF. Pan-HER inhibitor, varlitinib (ASLAN001) disrupts HER/ERK signaling and causes apoptosis in triple negative breast cancer cells. AACR Meeting Abstracts, Apr 2017; 2017: 2087.

38.   Tseng LM, Huang TT, Huang CT, Lau KY, Liu CY, Shiau CW, Chen KF. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. AACR Meeting Abstracts, Apr 2017; 2017: 4201.

39.   Liu CY, Hung MH, Tsai MH, Chu PY, Huang TT, Huang CT, Shiau CW, Chen KF.  Targeting SHP-1/p-Lyn signaling shows therapeutic potential in diffuse large B-cell lymphoma. AACR Meeting Abstracts, Apr 2017; 2017: 4192.

40.   Liu CY, Huang TT, Lee CH, Wang WL, Lee HC, Tseng LM. Kynurenine-3-monooxygenase (KMO) protein promotes triple negative breast cancer progression. ESMO 2017 Congress, 8-12 September, Madrid, Spain. Abstract (poster No. 9P)

41.   Chen KF, Liu CY, Chao TI, Chu PY, Huang TT, Wang WL, Lee CH, Lau KY, Tsai WC, Shiau CW, Tseng LM. SHP-1 agonist SC-43 enhanced the anti-tumor effect of docetaxel through suppressing p-STAT3 in triple negative breast cancer cells. ESMO 2017 Congress, 8-12 September, Madrid, Spain. Abstract (poster No. 11P)

42.   Huang YH, Chu PY, Chen JL, Huang CT, Lee CH, Lau KY, Wang WL, Wang YL,  Lien PJ, Tseng LM, Liu CY(*). SET overexpression is associated with recurrence-free survival in patients with primary breast cancer receiving adjuvant tamoxifen treatment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4612.

43.   Ji-Lin Chen, Wen-Chun Tsai, Tien-Yun Lan, Chun-Teng Huang, Pei-Yi Chu, Chia-Han Lee, Ka-Yi Lau, Wan-Lun Wang, Kuen-Feng Chen, Chung-Wai Shiau, Chun-Yu Liu. SET/PP2A/SHP-1/Lyn oncogenic signaling contributes to tumor aggressiveness in diffuse large B cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4372.

44.   MEK inhibitor cobimetinib induces immunogenic cell death and immune-modulatory effects in triple negative breast cancer”” San Antonio Breast Cancer Symposium (SABCS), December 4-8, 2018. Abstract P4-06-21

45.   C-Y. Liu , C-H. Lee , J-L. Chen , T-T. Huang , S-H. Yang , J-K. Jiang , W-S. Chen, KD. Lee, H-W. Teng. Kynurenine 3-monooxygenase as a potential biomarker for colorectal cancer. Annals of Oncology, Volume 29, viii200 (ESMO 2018 abstract 602P)

46.   23th Taiwan Joint Cancer Conference (TJCC) 2018: Abstract 23rd-B1-052: Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression in an enzyme-independent manner

47.   Chun-Yu Liu, Tzu-Ting Huang, Ji-Lin Chen, Chia-Han Lee, Wan-Lun Wang, Ka-Yi Lau, Chun-Teng Huang, Pei-Yi Chu, Hsin-Chen Lee,Ling-Ming Tseng. Kynurenine 3-monooxygenase (KMO) acts as a novel oncoprotein in triple negative breast cancer. AACR; Cancer Res 2019: Abstract nr 1711.

48.   C. Liu, K. Lau, J. Chen, P. Chu, C. Huang, W. Wang, P. Lien, L. Tseng. Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer. Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253 (ESMO 2019 abstract 1234P)

49.   C -Y Liu, Y -F Tsai, F -M Lin, J -C Wu, Y -S Lin, T -C Chao, K -L King, P -J Lien, J Wang, Y -H Lin, Y -C Lai, H B Hsieh, A Saklecha, J -M Lai, S -E Chang, M Javey, D Watson, R Mei, L -M Tseng. Novel blood based circulating tumour cell biomarker for breast cancer detection. Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, mdz240.080 (ESMO 2019 abstract 256P)

50.   24th Taiwan Joint Cancer Conference (TJCC) 2019: Abstract 24th-B124: MEK Inhibitor Elicits Immunogenic Cell Death and Anti-Tumor Immunity in Triple Negative Breast Cancer

51.   Global Breast Cancer Conference (GBCC) 2020: ABS-0095: Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression

52.   Chun-Yu Liu, Ji-Lin Chen, Yi-Ting Yang, Yi-Fang Tsai, Ta-Chung Chao, Kien Thiam Tan, Wan-Lun Wang, Pei-Ju Lien, Shu-Jen Chen and Ling-Ming Tseng. Abstract 6468: Prognostic genomic alterations associated with recurrence after primary therapy for patients with luminal B breast cancer. Cancer Res 2020 (80) (16 Supplement) 6468. AACR Annual Meeting 2020

53.   Chun-Yu Liu; Ji-Lin Chen; Chun-Teng Huang; Pei-Yi Chu; Mei-Fang Tseng; Yu-Hsuan Lee; Wan-Lun Wang; Ling-Ming Tseng. Abstract 2486: Pleiotropic anti-cancer effects of STING in estrogen receptor positive breast cancer cells. Cancer Res (2021) 81 (13_Supplement): 2486. AACR Annual Meeting 2021

54.   25th Taiwan Joint Cancer Conference (TJCC) 2021: Abstract 25th-C7-033: Prognostic value of glycoprotein non-metastatic B and its correlation with epithelial-mesenchymal transition in triple-negative breast cancer

55.   Chun-Yu Liu; Ji-Lin Chen; Pei-Yi Chu; Chun-Teng Huang; Wan-Lun Wang; Chi-Cheng Huang; Po-Han Lin; Ling-Ming Tseng. Abstract 5127: Significance of Trop-2 in HER2-positive breast cancer. Cancer Res (2022) 82 (12_Supplement): 5127. AACR Annual Meeting 2022

56.   Global Breast Cancer Conference (GBCC) 2022: ABS-0273: Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model

57.   26th Taiwan Joint Cancer Conference (TJCC) 2022: Abstract 26th-BT-064: Trop-2 expression contributes to the emergence of resistance to HER2-targeted therapy in HER2-positive breast cancer.

58. Chun-Yu Liu, Chi-Cheng Huang, Yi-Fang Tsai, Ta-Chung Chao, Yen-Shu Lin, Chin-Jung Feng, Jiun-I Lai, Ji-Lin Chen, Yen-Jen Chen, Jen-Hwey Chiu, Chih-Yi Hsu, Ling-Ming Tseng; Abstract P6-01-45: Correlation of an immune-related 8-gene panel with the efficacy of neoadjuvant chemotherapy for breast cancer. Cancer Res 1 March 2023; 83 (5_Supplement): P6–01–45. 2022 San Antonio Breast Cancer Symposium.

59. Chun-Yu Liu, Chi-Cheng Huang, Ji-Lin Chen, Yi-Fang Tsai, Ta-Chung Chao, Pei-Ju Lien, Yen-Shu Lin, Chin-Jung Feng, Yen-Jen Chen, Jiun-I Lai, Jen-Hwey Chiu, Chih-Yi Hsu, Ling-Ming Tseng. Characteristics of peripheral blood T cell receptor repertoire and correlation with response to chemotherapy in patients with breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Cancer Res 2023;83(7_Suppl):Abstract nr 2271.

60. Global Breast Cancer Conference (GBCC) 2023: Establishing the correlation of an 8-gene set of immune-response gene expression profiling with pathological complete response neoadjuvant chemotherapy in primary breast cancer patients.

61. 27th Taiwan Joint Cancer Conference (TJCC) 2023: Abstract C-001: Characteristics of T cell receptor repertoire in patients with breast cancer.

62. Chun-Yu Liu, Ji-Lin Chen, Yi-Fang Tsai, Ta-Chung Chao, Wan-Lun Wang, Pei-Ju Lien, Chih-Yi Hsu, Jiun-I Lai, Chi-Cheng Huang, Jen-Hwey Chiu, Ling-Ming Tseng. Role of ITGB2 in patients with luminal B1 breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7653.

63. Global Breast Cancer Conference (GBCC) 2024: Clinical and biological significance of T-cell receptor repertoire in patients with breast cancer

64. Chun-Yu Liu, Ji-Lin Chen, Chun-Fu Lin, Jui-To Wang, Wei-Hsin Wang, Cheng-chia Lee, Hsin-Hung Chen, Yi-Wei Chen, Shih-Chieh Lin, Chih-Chun Wu, Chi-Cheng Huang, Sanford P. C. Hsu. Genomic landscape and prognostic indicators in Taiwanese high-grade glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3331.

65. 29th Taiwan Joint Cancer Conference (TJCC) 2025: Abstract C1-005: Identifying Biomarkers for Early Recurrence in Luminal B1 Breast Cancer: The Role of ITGB2.